The most frequently reported adverse drug reactions (ADRs) (incidence ≥ 10% in the INTELENCE arm) of all intensities occurring in the Phase III studies were rash (17.0% in the INTELENCE arm versus 9.4% in the placebo arm), diarrhoea (15.0% versus 20.4%) and nausea (13.9% versus 11.1%).